PALO ALTO, Calif., Feb. 1 Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the 12th Annual BIO CEO & Investor Conference in New York City on Tuesday, February 9 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA®, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA®, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.